Myomo Reports Q3 2026 Revenue Growth of 22% and Improved Gross Margins
Myomo (MYO) reported strong third-quarter 2026 financial results, highlighted by a 22% year-over-year revenue increase to $12.3 million. This growth was driven by a 19% rise in unit sales and higher average selling prices. Notably, the company achieved significant margin expansion, with gross margins reaching 71.3%, up from 63.8% in the prior year due to lower material costs and better fixed-cost absorption. The company is successfully transitioning its business model, with recurring patient source revenue rising to 54% of total revenue as it shifts focus from direct-to-consumer advertising toward professional referral channels via MyoConnect. While pipeline additions saw a seasonal decline in Q3 due to staffing and summer seasonality, management noted that October performance has already rebounded by approximately 30%. Myomo's full-year revenue guidance has been narrowed to the upper end of its previous range, at $46 million to $47 million. The company also reached a near breakeven Adjusted EBITDA, marking a significant improvement from the losses reported in the third quarter of 2025.
Tickers: $MYO
Topics: EBITDA Breakeven Gross Margin Expansion Guidance Order Volume Revenue Growth